Navigation Links
Cepheid Reports Fourth Quarter and Full Year 2011 Results
Date:1/26/2012

SUNNYVALE, Calif., Jan. 26, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2011 of $80.1 million.  Net loss was $1.6 million, or $(0.03) per share, which compares to revenue of $58.7 million and net income of $1.3 million, or $0.02 per diluted share, in the fourth quarter of 2010.  As anticipated, the fourth quarter net loss reflected a one-time, non-cash charge to cost of sales of $5.4 million, or $0.08 per share, associated with the termination of a patent license.

Excluding stock compensation expenses, the non-cash charge of $5.4 million associated with the termination of a patent license, and amortization of acquired intangibles, non-GAAP net income for the fourth quarter of 2011 was $9.4 million, or $0.14 per share.  This compares to a non-GAAP net income of $6.1 million, or $0.09 per share, in the fourth quarter of 2010.

Fiscal 2011 OverviewFor the year ended December 31, 2011, Cepheid reported revenue of $277.6 million which compares to revenue of $212.5 million in 2010.  Net income for the year was $2.6 million, or $0.04 per diluted share, which compares to a net loss of $5.9 million, or $(0.10) per share, in 2010.  Excluding stock compensation expenses, the non-cash charge of $5.4 million associated with the termination of a patent license, and amortization of acquired intangibles, non-GAAP net income for the year was $29.6 million, or $0.44 per share.  This compares to a non-GAAP net income of $12.5 million, or $0.20 per share, for the full year 2010.

"GeneXpert system placements continued at a very strong pace in the fourth quarter contributing to a record number of placements during 2011, in both our commercial and High Burden Developing Country programs," said John Bishop, Cepheid's Chief Executive Officer.  "The demand for our GeneXpert systems has continued to grow
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cepheid Welcomes Senior Vice President of Human Resources
2. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
3. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
4. Cepheid to Webcast Upcoming Financial Presentations
5. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
6. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
8. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
9. Cepheid Reports 2009 First Quarter Results
10. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
11. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
(Date:11/18/2014)... Brunswick, NJ (PRWEB) November 18, 2014 ... Data Quality and Transparency Reporting solutions, announced today ... gone live using its Consummate Providerâ„¢ solution in ... Providerâ„¢ is a Global, SaaS based, Data Quality ... organizations and their third party Providers improve their ...
(Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, Inc. ... in connection with the acquisition of Durata Therapeutics, Inc. ... connection with the termination of PDL,s credit agreement with ... outstanding of $40 million, accrued interest, and prepayment and ... into a structured financing transaction with Durata in which ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today the formation of a Medical ... to the Company as it advances the Phase ... the treatment of cutaneous T-cell lymphoma (CTCL), a ...
Breaking Biology Technology:Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6
... the Association of ... Chinese Canadian Entrepreneurs, TORONTO, April 7 ... and developing the next wave of,antibody therapeutics, today announced that ... "Most Innovative" award at the,Chinese Canadian Entrepreneur Awards, held on ...
... today that,it received notice from Israel,s Chief Scientist,s Office ... D-Pharm,s R&D programs with a,total grant of up to ... PhD, CEO and President of D-Pharm, said "We are ... its firm support over the years,from the time of ...
... computer contains two different types of components: magnetic components, ... logic operations. A University of Missouri researcher, as part ... these two functions in a single hybrid material. This ... logical functions and is expected to permit the design ...
Cached Biology Technology:ARIUS recognized for entrepreneurial excellence 2D-Pharm Secures Funding From Israel's Chief Scientist's Office 2Hybrid computer materials may lead to faster, cheaper technology 2
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... has long been known that distinctive blue flashes--a type ... environments are caused by tiny, unicellular plankton known as ... time, detailed the potential mechanism for this bioluminesence. ... Science Foundation, is reported by Susan Smith of Emory ...
... Scientists are reporting that household washing machines seem to ... bits of polyester and acrylic smaller than the head ... on ocean shorelines worldwide. Their report describing this potentially ... & Technology . Mark Browne and colleagues explain ...
... the science of sound will be featured at the 162nd ... 31 November 4, 2011, at the Town and Country ... research spanning a diverse array of disciplines, including medicine, music, ... to attend the meeting free of charge. Registration information is ...
Cached Biology News:Explanation for glowing seas suggested 2Sound research at acoustical society meeting 2Sound research at acoustical society meeting 3Sound research at acoustical society meeting 4Sound research at acoustical society meeting 5Sound research at acoustical society meeting 6Sound research at acoustical society meeting 7Sound research at acoustical society meeting 8Sound research at acoustical society meeting 9Sound research at acoustical society meeting 10Sound research at acoustical society meeting 11